Sign In
Buy DYAI
$1.05
-0.0200 (-1.87%)
At Close: Jul 31, 2026
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
04:51pm, Wednesday, 25'th Mar 2026
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product sales
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
07:20am, Monday, 16'th Mar 2026
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company produci
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
04:10pm, Wednesday, 11'th Mar 2026
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
07:20am, Wednesday, 04'th Mar 2026
JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechn
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milesto
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
07:25am, Tuesday, 17'th Feb 2026
JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology
Dyadic International (NASDAQ:DYAI) Share Price Crosses Below 50 Day Moving Average – Should You Sell?
04:52am, Friday, 16'th Jan 2026
Dyadic International Inc. (NASDAQ: DYAI - Get Free Report)'s share price crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $0.94 and tr
JUPITER, Fla. , Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company producing precision-enginee
JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzy
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
10:57am, Tuesday, 09'th Dec 2025
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR)
02:20am, Wednesday, 03'rd Dec 2025
Dyadic International (NASDAQ: DYAI - Get Free Report) and Kezar Life Sciences (NASDAQ: KZR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare
JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free prot
Bandera Partners LLC Has $1.37 Million Holdings in Dyadic International Inc. $DYAI
03:36am, Tuesday, 25'th Nov 2025
Bandera Partners LLC decreased its position in shares of Dyadic International Inc. (NASDAQ: DYAI) by 11.7% in the undefined quarter, according to its most recent Form 13F filing with the Securities an
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript
09:01pm, Wednesday, 12'th Nov 2025
Dyadic International, Inc. ( DYAI ) Q3 2025 Earnings Call November 12, 2025 5:00 PM EST Company Participants Ping Rawson - Chief Financial Officer Joseph Hazelton - President & COO Mark Emalfarb - Fou
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
04:05pm, Wednesday, 12'th Nov 2025
Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations Advanced
